Back
 Health  Vol.8 No.9 , June 2016
A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir
Abstract: Background and Aims: Treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and NS3A (non-structural protein 3A) protease inhibitor simeprevir resulted in high rates of sustained virological response in chronic hepatitis C Genotype 4. Methods: We conducted a real life study on Egyptian patients coming to tropical medicine department clinic at El Mery main university hospital from February 2015 to February 2016 for treatment naive and treatment experienced patients with chronic HCV genotype 4, including cirrhotics and non cirrhotics. Naive (cir-rhotics and non cirrhotics) and relapsers (non cirrhotics) received nucleotide polymerase inhibitor sofosbuvir and NS3A inhibitor simeprevir once daily for 12 weeks and 24 weeks for relapser cirrhotic patients. The primary end point was a sustained virologic response at 12 weeks after end of treatment. An informed consent was obtained from each patient at the beginning of the study (Real life study: a study on Egyptian patients when the drug was available in the market). Results: 30 naive patients with HCV genotype 4 and 20 relapsers (10 non cirrhotic and 10 cirrhotic patients) were enrolled. Patient inclusion criteria: Naive patients are those who tested positive for HCV RNA by PCR and had no experience to HCV treatment; Relapsers are those who tested positive for HCV RNA by PCR and had a previous treatment for HCV. Cirrhosis was diagnosed on ultrasound basis. Mean age was 53.57 ± 10.682 years old in naive patients and 48.30 ± 5.100 years old in relapsers. Median baseline HCV RNA was 360,069 IU/mL for naive patients and 1,245,000 IU/mL for relapsers; using Fib4 20% of naive patients were F3-F4, while 40% of relapsers were F3-F4. Degree of fibrosis was confirmed by fibrotest in relapsers. Upon treatment of patients with sofosbuvir and semiprevir once daily for 12 weeks and 24 weeks only to cirrhotic relapsers, end of treatment PCR was negative in 100% in all groups including cirrhotics and non cirrhotics. Primary end point (SVR 12) was achieved in 100% of all patients. Second end point (SVR 24) was achieved in 96.6% of naive pa-ients; SVR 24 for non-cirrhotic relapsers was achieved in 100% of patients and in 90% of cirrhotic relapsers. One patient had transient total bilirubin elevations without increased ALT (alanine aminotransferase) or AST (aspartate aminotransferase). One patient developed cutaneous rash. Conclusion: Once daily sofosbuvir and simeprevir for 12 weeks provided high rate of sustained virological response among treatment naive and treatment experienced patients with HCV genotype IV.
Cite this paper: Hanno, A. , Elwazzan, D. , Ibrahim, M. and Hafez, R. (2016) A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir. Health, 8, 780-786. doi: 10.4236/health.2016.89082.
References

[1]   Mohlman, M.K., Saleh, D.A., Ezzat, S., Abdel-Hamid, M., Korba, B., Shettyia, K., et al. (2015) Viral Transmission Risk Factors in an Egyptian Population with High Hepatitis C prevalence. BMC Public Health, 15, 1030.
http://dx.doi.org/10.1186/s12889-015-2369-y

[2]   Breban, R., Doss, W., Esmat, G., Elsayed, M., Hellard, M., Ayscue, P., et al. (2013) Towards Realistic Estimates of HCV Incidence in Egypt. Journal of Viral Hepatitis, 20, 294-296.
http://dx.doi.org/10.1111/j.1365-2893.2012.01650.x

[3]   Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. and Raza, H. (2014) Global Epidemiology and Genotype Distribution of the Hepatitis C Virus Infection. Journal of Hepatology, 61, S45-S57.
http://dx.doi.org/10.1016/j.jhep.2014.07.027

[4]   Maasoumy, B. and Wedemeyer, H. (2012) Natural History of Acute and Chronic Hepatitis. Best Practice & Research Clinical Gastroenterology, 26, 401-412.
http://dx.doi.org/10.1016/j.bpg.2012.09.009

[5]   Gomez, E.V., Bertot, L.C., Rodriguez, Y.S., Gonzalez, A.T., Perez, Y.M. and Garcia, A.Y. (2014) The Natural History of HCV-Related Cirrhosis and Its Temporal Progression across the Different Clinical Stages. Hepatology International, 8, 527-539.
http://dx.doi.org/10.1007/s12072-014-9565-1

[6]   Nguyen, M.H, and Keeffe, E.B. (2005) Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6. Clinical Gastroenterology and Hepatology, 3, S97-S101.
http://dx.doi.org/10.1016/S1542-3565(05)00711-1

[7]   Hayashi, N. and Takehara, T. (2006) Antiviral Therapy for Chronic Hepatitis C: Past, Present, and Future. Journal of Gastroenterology, 41, 17-27.
http://dx.doi.org/10.1007/s00535-005-1740-7

[8]   Kamal, S.M., El Tawil, A.A., Nakano, T., He, Q., Rasenack, J., Hakam, S.A., et al. (2005) Peginterferon α-2b and Ribavirin Therapy in Chronic Hepatitis C Genotype 4: Impact of Treatment Duration and Viral Kinetics on Sustained Virological Response. Gut, 54, 858-866.
http://dx.doi.org/10.1136/gut.2004.057182

[9]   Sulkowsk, M.S., Cooper, C., Hunyady, B., Jia, J., Ogurtsov, P., Peck-Radosavljevic, M., et al. (2011) Management of Adverse Effects of Peg-IFN and Ribavirin Therapy for Hepatitis C. Nature Reviews Gastroenterology and Hepatology, 8, 212-223.
http://dx.doi.org/10.1038/nrgastro.2011.21

[10]   Kowdley, K.V. (2005) Hematologic Side Effects of Interferon and Ribavirin Therapy. Journal of Clinical Gastroenterology, 39, S3-S8.
http://dx.doi.org/10.1097/01.mcg.0000145494.76305.11

[11]   Kohli, A., Shaffer, A., Sherman, A. and Kottilil, S. (2014) Treatment of Hepatitis C; A Systematic Review. Journal of the American Medical Association, 312, 631-640.
http://dx.doi.org/10.1001/jama.2014.7085

[12]   Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., et al. (2011) Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. The New England Journal of Medicine, 364, 1207-1217.
http://dx.doi.org/10.1056/NEJMoa1009482

[13]   Sherman, K., Flamm, S.L., Afdhal, N.H., Nelson, D.R., Sulkowski, M.S., Everson, G.T., et al. (2011) Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. The New England Journal of Medicine, 365, 1014-1024.
http://dx.doi.org/10.1056/NEJMoa1014463

[14]   Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., et al. (2009) PROVE2 Study Team. Telaprevir and PEGinterferon with or without Ribavirin for Chronic HCV Infection. The New England Journal of Medicine, 360, 1839-1850.
http://dx.doi.org/10.1056/NEJMoa0807650

[15]   Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., et al. (2011) Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. The New England Journal of Medicine, 364, 1207-1217.
http://dx.doi.org/10.1056/NEJMoa1009482

[16]   Zeuzem, S., Andreone, P., Stanislas, P., Lawitz, E., Diago, M., Roberts, S., et al. (2011) Telaprevir for Retreatment of HCV Infection. The New England Journal of Medicine, 364, 2417-2428.
http://dx.doi.org/10.1056/NEJMoa1013086

[17]   Lenz, O., Vijgen, L., Berke, J.M., Cummings, M.D., Fevery, B., Monika Peeters, M., et al. (2013) Virologic Response and Characterisation of HCV Genotype 2-6 in Patients Receiving TMC435 Monotherapy (Study TMC435-C202). Journal of Hepatology, 58, 445-451.
http://dx.doi.org/10.1016/j.jhep.2012.10.028

[18]   Jensen, D.M., O’Leary, J., Pokros, P., Sherman, K., Kwo, P., Mailliard, M., et al. (2014) Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real World Experience in a Diverse, Longuitudinal Observational Cohort. Hepatology, 40, 219A-220A.

[19]   Moreno, C., Hezode, C., Marcellin, P., Bourgeois, S., Francque, S., Samuel, D., et al. (2015) Efficacy and Safety of Simeprevir with PegIFN/Ribavirin in Naive or Experienced Patients Infected with Chronic HCV Genotype 4. Journal of Hepatology, 62, 1047-1055.
http://dx.doi.org/10.1016/j.jhep.2014.12.031

[20]   Hill, A. and Saleem, J. (2014) Effects of Sustained Virological Response on the Risk of Liver Transplant, Hepatocellular Carcinoma, Death and Re-Infection: Meta-Analysis of 129 Studies in 34,563 Patients with Hepatitis C Infection. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, 7-11 November 2014.

[21]   George, S.L., Bacon, B.R., Brunt, E.M., Mihindukulasuriya, K.L., Hoffmann, J. and Di Bisceglie, A.M. (2009) Clinical, Virologic, Histologic, and Biochemical Outcomes after Successful HCV Therapy: A 5-Year Follow-Up of 150 Patients. Hepatology, 49, 729-738.
http://dx.doi.org/10.1002/hep.22694

[22]   Mira, J.A., Rivero-Juarez, A., Lopez-Cortes, L.F., Giron-Gonzalez, J.A., Tellez, F., de los Santos-Gil, I., et al. (2013) Benefits from Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus-Coinfected Patients with Compensated Cirrhosis. Clinical Infectious Diseases, 56, 1646-1653.
http://dx.doi.org/10.1093/cid/cit103

[23]   El Raziky, M., Fathalah, W.F., El-Akel, W.A., Salama, A., Esmat, G., Mabrouk, M., et al. (2013) The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepatitis Monthly, 13, e10069.
http://dx.doi.org/10.5812/hepatmon.10069

[24]   Esmat, G., El Kassas, M., Hassany, M., Gamil, M. and El Raziky, M. (2014) Optimizing Treatment for HCV Genotype 4: PEG-IFN Alfa 2a vs. PEG-IFN Alfa 2b, the Debate Continues. Liver International, 34, 24-28.
http://dx.doi.org/10.1111/liv.12397

[25]   Association for the Study of Liver Diseases (2015) OSIRIS Poster, Presented at the Liver Meeting. The Annual Meeting of the American.

[26]   Lawitz, E., Sulkowski, M.S., Ghalib, R., et al. (2014) Simeprevir plus Sofosbuvir, with or without Ribavirin, to Treat Chronic Infection with Hepatitis C Virus Genotype 1 in Non-Responders to PEGylated Interferon and Ribavirin and Treatment-Naive Patients: The COSMOS Randomised Study. The Lancet, 384, 1756-1765.
http://dx.doi.org/10.1016/S0140-6736(14)61036-9

[27]   Lawitz, E., Matusow, G., DeJesus, E., Yoshida, E., Felizarta, F., Ghalib, R., et al. (2015) A Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of 12 Weeks of Simeprevir (SMV) plus Sofosbuvir (SOF) in Treatment-Naive or -Experienced Patients with Chronic HCV Geno-type 1 Infection and Cirrhosis: OPTIMIST-2. Journal of Hepatology, 62, S264-S265.
http://dx.doi.org/10.1016/S0168-8278(15)30158-6

[28]   Hézode, C., Asselah, T., Reddy, K.R., Hassanein, T., Berenguer, M., Fleischer-Stepniewska, K., et al. (2015) Ombitasvir plus Paritaprevir plus Ritonavir with or without Ribavirin in Treatment-Naive and Treatment-Experienced Patients with Genotype 4 Chronic Hepatitis C Virus Infection (PEARL-I): A Randomised, Open-Label Trial. The Lancet, 385, 2502-2509.
http://dx.doi.org/10.1016/S0140-6736(15)60159-3

[29]   Flamm, S.L., Everson, G.T., Charlton, M.R., Denning, J.M., Arterburn, S., Brandt-Sarif, T., et al. (2014) Ledipasvir/ Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multi-center Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, 7-11 November 2014.

[30]   Forns, X., Lawitz, E., Zeuzem, S., Gane, E., Bronowicki, J.P., Andreone, P., et al. (2014) Simeprevir with Peginterferon and Ribavirin Leads to High Rates of SVR in Patients with HCV Genotype 1 Who Relapsed after Previous Therapy: A Phase 3 Trial. Gastroenterology, 146, 1669-1679.
http://dx.doi.org/10.1053/j.gastro.2014.02.051

[31]   Jacobson, I.M., Dore, G.J., Foster, G.R., Fried, M.W., Radu, M., Rafalsky, V.V., et al. (2014) Simeprevir with Pegylated Interferon Alfa 2a plus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection (QUEST-1): A Phase 3, Randomised, Double-Blind, Placebo-Controlled trial. The Lancet, 384, 403-413.
http://dx.doi.org/10.1016/S0140-6736(14)60494-3

[32]   Manns, M., Marcellin, P., Poordad, F., de Araujo, E.S., Buti, M., Horsmans, Y., et al. (2014) Simeprevir with Pegylated Interferon Alfa 2a or 2b plus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection (QUEST-2): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet, 384, 414-426.
http://dx.doi.org/10.1016/S0140-6736(14)60538-9

 
 
Top